Michael Sension

2.0k total citations
34 papers, 1.2k citations indexed

About

Michael Sension is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Michael Sension has authored 34 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Infectious Diseases, 29 papers in Virology and 11 papers in Emergency Medicine. Recurrent topics in Michael Sension's work include HIV/AIDS drug development and treatment (32 papers), HIV Research and Treatment (29 papers) and HIV/AIDS Research and Interventions (20 papers). Michael Sension is often cited by papers focused on HIV/AIDS drug development and treatment (32 papers), HIV Research and Treatment (29 papers) and HIV/AIDS Research and Interventions (20 papers). Michael Sension collaborates with scholars based in United States, United Kingdom and Belgium. Michael Sension's co-authors include Shannon Schrader, Alexandra Thiry, Willy Rozenbaum, Michael Giordano, Vadim Pokrovskiy, Marcus A. Conant, Jaime E. Hernández, Vanessa C. Williams, Kathleen Squires and Adriano Lazzarin and has published in prestigious journals such as Clinical Infectious Diseases, Transplantation and AIDS.

In The Last Decade

Michael Sension

33 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Sension United States	17	1.0k	824	455	123	51	34	1.2k
Donnie McGrath United States	14	970 1.0×	683 0.8×	372 0.8×	154 1.3×	54 1.1×	19	1.1k
Victoria Wirtz United States	11	820 0.8×	591 0.7×	359 0.8×	100 0.8×	50 1.0×	21	904
Nicholaos Bellos United States	11	825 0.8×	621 0.8×	312 0.7×	134 1.1×	29 0.6×	15	936
David Pizzuti United States	5	490 0.5×	386 0.5×	317 0.7×	109 0.9×	38 0.7×	5	687
Paul Wannamaker United States	9	705 0.7×	534 0.6×	275 0.6×	116 0.9×	28 0.5×	16	1.1k
Miguel A García-Viejo Spain	9	761 0.8×	470 0.6×	533 1.2×	317 2.6×	45 0.9×	11	1.0k
Marek Beniowski Poland	13	690 0.7×	272 0.3×	429 0.9×	288 2.3×	35 0.7×	32	890
Paola Cicconi Italy	17	489 0.5×	369 0.4×	301 0.7×	351 2.9×	32 0.6×	45	881
Maria Vittoria Cossu Italy	15	387 0.4×	344 0.4×	141 0.3×	114 0.9×	72 1.4×	55	641
Heather A. Algren United States	6	776 0.8×	657 0.8×	925 2.0×	100 0.8×	53 1.0×	7	1.1k

Countries citing papers authored by Michael Sension

Since Specialization

Citations

This map shows the geographic impact of Michael Sension's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Sension with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Sension more than expected).

Fields of papers citing papers by Michael Sension

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Sension. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Sension. The network helps show where Michael Sension may publish in the future.

Co-authorship network of co-authors of Michael Sension

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Sension. A scholar is included among the top collaborators of Michael Sension based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Sension. Michael Sension is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mounzer, Karam, Laurence Brunet, Michael Sension, et al.. (2025). Weight loss with real-world doravirine use in the OPERA cohort: a US-based cohort study. AIDS Research and Therapy. 22(1). 64–64.

Pierone, Gerald, Jennifer S Fusco, Laurence Brunet, et al.. (2023). 1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Mounzer, Karam, Laurence Brunet, Jennifer S Fusco, et al.. (2023). Immune response to ART initiation in advanced HIV infection. HIV Medicine. 24(6). 716–726. 8 indexed citations

Sension, Michael, Laurence Brunet, Jennifer S Fusco, et al.. (2023). Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort. Infectious Diseases and Therapy. 12(12). 2807–2817. 30 indexed citations

Sension, Michael, Jennifer S Fusco, Laurence Brunet, et al.. (2023). 1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA® Cohort. Open Forum Infectious Diseases. 10(Supplement_2). 7 indexed citations

Sension, Michael, Jennifer S Fusco, Laurence Brunet, et al.. (2023). 1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort. Open Forum Infectious Diseases. 10(Supplement_2). 17 indexed citations

Sinclair, Gary, Michael Sension, Alexandra W. Dretler, et al.. (2023). 1607. Clinical Outcomes at Month 6 after Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND). Open Forum Infectious Diseases. 10(Supplement_2). 5 indexed citations

Mounzer, Karam, Laurence Brunet, Jennifer S Fusco, et al.. (2022). Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens. Open Forum Infectious Diseases. 9(3). ofac018–ofac018. 23 indexed citations

Hicks, Charles B., Patrick G. Clay, Robert Redfield, et al.. (2012). Safety, Tolerability, and Efficacy of KP-1461 as Monotherapy for 124 Days in Antiretroviral-Experienced, HIV Type 1-Infected Subjects. AIDS Research and Human Retroviruses. 29(2). 250–255. 13 indexed citations

10.

Hicks, Charles B., Edwin DeJesus, Louis Sloan, et al.. (2009). Comparison of Once-Daily Fosamprenavir Boosted with Either 100 or 200 mg of Ritonavir, in Combination with Abacavir/Lamivudine: 96-Week Results from COL100758. AIDS Research and Human Retroviruses. 25(4). 395–403. 17 indexed citations

11.

Sension, Michael, Beatriz Grinsztejn, Jean‐Michel Molina, et al.. (2009). Improvement in Lipid Profiles in Antiretroviral-Experienced HIV-Positive Patients With Hyperlipidemia After a Switch to Unboosted Atazanavir. JAIDS Journal of Acquired Immune Deficiency Syndromes. 51(2). 153–162. 28 indexed citations

12.

Elion, Richard, Edwin DeJesus, Michael Sension, et al.. (2008). Once-Daily Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir for the Treatment of HIV-1 Infection in Antiretroviral-Naïve Patients: A 48-Week Pilot Study. HIV Clinical Trials. 9(3). 152–163. 21 indexed citations

13.

Sension, Michael & Peter J. Piliero. (2007). Ritonavir-Boosted Protease Inhibitors: Impact of Ritonavir on Toxicities in Treatment-Experienced Patients. Journal of the Association of Nurses in AIDS Care. 18(1). 36–47. 5 indexed citations

14.

Sension, Michael. (2007). Long-Term Suppression of HIV Infection: Benefits and Limitations of Current Treatment Options. Journal of the Association of Nurses in AIDS Care. 18(1). S2–S10. 12 indexed citations

15.

Keiser, Philip, Michael Sension, Edwin DeJesus, et al.. (2005). Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infectious Diseases. 5(1). 2–2. 31 indexed citations

16.

Squires, Kathleen, Adriano Lazzarin, William G. Powderly, et al.. (2004). Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 36(5). 1011–1019. 238 indexed citations

17.

Sension, Michael. (2004). Initial Therapy for Human Immunodeficiency Virus: Broadening the Options. HIV Clinical Trials. 5(2). 99–111. 2 indexed citations

18.

DeJesus, E, Dennis McCarty, Charles Farthing, et al.. (2004). Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial. Clinical Infectious Diseases. 39(3). 411–418. 50 indexed citations

19.

Wood, Robin, Praphan Phanuphak, Pedro Cahn, et al.. (2004). Long-Term Efficacy and Safety of Atazanavir With Stavudine and Lamivudine in Patients Previously Treated With Nelfinavir or Atazanavir. JAIDS Journal of Acquired Immune Deficiency Syndromes. 36(2). 684–692. 74 indexed citations

20.

Sension, Michael, et al.. (2001). Challenges of Antiretroviral Treatment in Transient and Drug-Using Populations: The SUN Study. AIDS Patient Care and STDs. 15(3). 129–136. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact